News | ASGCT - American Society of Gene & Cell Therapy | ASGCT - American Society of Gene & Cell Therapy

FDA Approves Zolgensma, Landmark AAV-Delivered Gene Therapy to Treat Spinal Muscular Atrophy

May 24, 2019

Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular atrophy (SMA) also known as AVXS-101, was approved for clinical use in the United States by the Food and Drug Administration today.

Annual Meeting 2019 | ASGCT News | Gene Therapy Approval

Read Full Story

22nd Annual Meeting Recap

Edith Pfister, Ph.D. | May 16, 2019

Edith Pfister, Ph.D., associate editor of ASGCT's newsletter The Vector, not only attended the record-breaking ASGCT 22nd Annual Meeting but presented an abstract on the meeting's final day. Read about her experience and recap an incredible week of science.

Annual Meeting 2019

Read Full Story

The Case for Growth

Guangping Gao, Ph.D. | May 09, 2019

Following a record-breaking ASGCT Annual Meeting, the Society is ready to branch out and ensure its growth is sustainable.

Annual Meeting 2019 | ASGCT News | President's Message

Read Full Story

ASGCT To Honor Four Ground-Breaking Researchers at 22nd Annual Meeting

ASGCT Staff | March 26, 2019

ASGCT is proud to introduce the four recipients of the Society's 2019 Outstanding Achievement Award, Outstanding New Investigator Awards, and the Sonia Skarlatos Public Service Award.

Annual Meeting 2019 | ASGCT News

Read Full Story

Annual Meeting 2019

FDA Approves Zolgensma, Landmark AAV-Delivered Gene Therapy to Treat Spinal Muscular Atrophy

22nd Annual Meeting Recap

The Case for Growth

ASGCT To Honor Four Ground-Breaking Researchers at 22nd Annual Meeting

ASGCT Policy Summit